Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Mol Pharm. 2010 Aug 2;7(4):936–943. doi: 10.1021/mp100054m

Figure 3.

Figure 3

Representative 3D maximum intensity projection images (T1-weighted) of a tumor bearing mouse injected with G3-DOTA-Mn (G3-Mn) and peptide CLT1-targeted G3-DOTA-Mn (P-G3-Mn) nanoglobular MRI contrast agent at 30 μmol-Mn/kg. Solid arrows show urinary bladder and dashed arrows show tumor.